Baron SJ, et al. - As transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar rates of death or stroke at 2 years in patients with severe aortic stenosis (AS) at intermediate surgical risk, researchers compared the two procedures regarding cost-effectiveness. Between 2011 and 2014, TAVR or SAVR was done on 3110 intermediate-risk AS patients in the PARTNER-2 Trial. Observations revealed TAVR as economically dominant as it provided both greater quality-adjusted life expectancy and lower long-term costs compared with SAVR.